In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
|Videos|June 22, 2017
Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers
Author(s)Stephen M. Ansell, MD, PhD
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Related to this article
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
FDA Flashback: GI Cancer Decisions and News From July 2026
3
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
4
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
5